← Back to Search

Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment

N/A

Recruiting

Led By Juan Wisnivesky, MD, DrPh

Research Sponsored by Icahn School of Medicine at Mount Sinai

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up end of study, at 12 months

Awards & highlights

Study Summary

This trial will investigate whether cognitive rehabilitation can help improve cognition for patients with post-COVID-19 cognitive impairment, as well as collect preliminary data on potential connectivity networks underlying the effect of cognitive rehabilitation on cognitive improvements.

Who is the study for?

This trial is for English-speaking adults over 18 who are comfortable with technology and have had COVID-19. They must show mild to moderate cognitive impairment but can't have severe dementia, ongoing substance abuse, unstable health conditions that affect study participation, MRI contraindications like metal implants, or be engaged in other cognitive training.Check my eligibility

What is being tested?

The trial tests if cognitive rehabilitation helps people who've had COVID-19 recover from thinking problems. It compares this method to a brain health education program. The study also uses advanced brain scans (rsfMRI) to see how the treatment might change brain connections.See study design

What are the potential side effects?

Since the interventions involve non-invasive techniques such as education and exercises for the mind, side effects are minimal but may include fatigue or frustration due to the challenges of mental tasks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ end of study, at 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~end of study, at 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and end of study, at 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acceptability Scale

Dropout number

Enrollment yield

+5 more

Secondary outcome measures

NACC battery's abbreviated Multilingual Naming Test (MINT)

NACC battery's verbal phonemic and category fluency tests

National Alzheimer's Coordinating Center (NACC) battery's Number Span

+5 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Cognitive RehabilitationExperimental Treatment1 Intervention

Active Group participants will receive nine 1.5-h sessions of virtual (via Zoom platform) group-based training, three individual virtual 1-h training sessions, and approximately 20 h of home practice and CCT over 12 weeks.

Group II: Brain Health Education ProgramActive Control1 Intervention

The control group format will be twelve 1.5 or 1 h virtual sessions over 12 weeks, in addition to 20 h of home practice of a computerized control program (e.g., consisting of publicly available computer games such as sudoku and crossword puzzles).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cognitive Rehabilitation

2009

N/A

~700

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor

858 Previous Clinical Trials

524,226 Total Patients Enrolled

Juan Wisnivesky, MD, DrPhPrincipal InvestigatorIcahn School of Medicine at Mount Sinai

Media Library

Cognitive Rehabilitation Clinical Trial Eligibility Overview. Trial Name: NCT05498493 — N/A

Cognitive Impairment Research Study Groups: Cognitive Rehabilitation, Brain Health Education Program

Cognitive Impairment Clinical Trial 2023: Cognitive Rehabilitation Highlights & Side Effects. Trial Name: NCT05498493 — N/A

Cognitive Rehabilitation 2023 Treatment Timeline for Medical Study. Trial Name: NCT05498493 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the primary goal of this scientific experiment?

"This trial's primary outcome, evaluated at the conclusion of the study (12 months), will be dropout rate. Secondary outcomes include Symbol Digit Modalities Text (SDMT) reaction times in seconds; Hopkins Verbal Learning Test-Revised (HVLT-R) total score converted to a "T" score ranging from 20 to 80; and NACC battery's abbreviated Multilingual Naming Test (MINT)'s scores which can range from 0 - 32 with higher numbers implying better performance."

Answered by AI

How many individuals are involved in this trial?

"Affirmative. According to data provided on clinicaltrials.gov, the trial which was initially posted on September 1st 2022 is actively seeking enrolment of 60 individuals from a single medical centre."

Answered by AI

Does this research have any open enrollment slots?

"As per clinicaltrials.gov, this investigation is currently recruiting volunteers. It was initially posted on September 1st 2022 and the most recent update occurred August 18th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment

Juan P Wisnivesky 2022. "Cognitive Rehabilitation for Post-COVID-19 Cognitive Impairment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05498493.